Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4

References

• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331(6024):1565-70; PMID:21436444; https://doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37(5):430-9; PMID:21074057; https://doi.org/10.1053/j.seminoncol.2010.09.005
   PubMed Web of Science ®Google Scholar
• Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 2010; 11(12):1354-9; PMID:21154117
   PubMedGoogle Scholar
• Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11(11):805-12; PMID:22020206; https://doi.org/10.1038/nrc3153
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature 2014; 515(7528):496-8; PMID:25428495; https://doi.org/10.1038/515496a
   PubMed Web of Science ®Google Scholar
• Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015; 68(2):267-9; PMID:25824720; https://doi.org/10.1016/j.eururo.2015.02.032
   PubMed Web of Science ®Google Scholar
• Carosella ED, Rouas-Freiss N, Roux DT, Moreau P, LeMaoult J. HLA-G: An Immune Checkpoint Molecule. Adv Immunol 2015; 127:33-144; PMID: 26073983; https://doi.org/10.1016/bs.ai.2015.04.001
   PubMed Web of Science ®Google Scholar
• Agaugue S, Carosella ED, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 2011; 117(26):7021-31; PMID:21482709; https://doi.org/10.1182/blood-2010-07-294389
   PubMed Web of Science ®Google Scholar
• Loumagne L, Baudhuin J, Favier B, Montespan F, Carosella ED, Rouas-Freiss N. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. Int J Cancer 2014; 135(9):2107-17; PMID:24623585; https://doi.org/10.1002/ijc.28845
   PubMed Web of Science ®Google Scholar
• Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, López-Botet M.. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186(11):1809-1818; PMID:9382880; https://doi.org/10.1084/jem.186.11.1809
   PubMed Web of Science ®Google Scholar
• Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A.. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 1998; 160(7):3096-100; PMID:9531263
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Gao W, Li L, Cui X, Yang H, Lin W, Dang Q, Zhang N, Sun Y. Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10. Diagnostic pathology 2014; 9:85; PMID:24762057; https://doi.org/10.1186/1746-1596-9-85
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu J, Gao P, Wang Y, Liu C. Expression of Ig-like transcript 4 inhibitory receptor in human non-small cell lung cancer. Chest 2008; 134(4):783-8; PMID:18625675; https://doi.org/10.1378/chest.07-1100
   PubMed Web of Science ®Google Scholar
• Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol 2017; 43(3):604-11; PMID:27769635; https://doi.org/10.1016/j.ejso.2016.07.145
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine 2015; 373(17):1627-39; PMID:26412456; https://doi.org/10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515(7528):563-7; PMID:25428504; https://doi.org/10.1038/nature14011
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C, Benson P, Ho TH, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2015; 21(5):1071-7; PMID:25538263; https://doi.org/10.1158/1078-0432.CCR-14-1993
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2015; 33(13):1430-7; PMID:25452452; https://doi.org/10.1200/JCO.2014.59.0703
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373(19):1803-13; PMID:26406148; https://doi.org/10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Hassel JC. Ipilimumab plus nivolumab for advanced melanoma. Lancet Oncol 2016; 17(11):1471-2; PMID:27617662; https://doi.org/10.1016/S1470-2045(16)30409-0
   PubMed Web of Science ®Google Scholar
• Kourie HR, Klastersky JA. Side-effects of checkpoint inhibitor-based combination therapy. Curr Opin Oncol 2016; 28(4):306-13; PMID:27136134; https://doi.org/10.1097/CCO.0000000000000295
   PubMed Web of Science ®Google Scholar
• Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer research 2005; 65(22):10139-10144; PMID:16287995; https://doi.org/10.1158/0008-5472.CAN-05-0097
   PubMed Web of Science ®Google Scholar
• Naji A, Le Rond S, Durrbach A, Krawice-Radanne I, Creput C, Daouya M, Caumartin J, LeMaoult J, Carosella ED, Rouas-Freiss N. CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 2007; 110(12):3936-48; PMID:17804694; https://doi.org/10.1182/blood-2007-04-083139
   PubMed Web of Science ®Google Scholar
• LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007; 109(5):2040-48; PMID:17077329; https://doi.org/10.1182/blood-2006-05-024547
   PubMed Web of Science ®Google Scholar
• Djurisic S, Skibsted L, Hviid TV. A Phenotypic Analysis of Regulatory T Cells and Uterine NK Cells from First Trimester Pregnancies and Associations with HLA-G. Am J Reprod Immunol 2015; 74(5):427-44; PMID:26293482; https://doi.org/10.1111/aji.12421
   PubMed Web of Science ®Google Scholar
• Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003; 100(15):8856-61; PMID:12853576; https://doi.org/10.1073/pnas.1431057100
   PubMed Web of Science ®Google Scholar
• Kang X, Kim J, Deng M, John S, Chen H, Wu G, Phan H, Zhang CC. Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell cycle 2016; 15(1):25-40; PMID:26636629; https://doi.org/10.1080/15384101.2015.1121324
   PubMed Web of Science ®Google Scholar
• Zhang P, Yu S, Li H, Liu C, Li J, Lin W, Gao A, Wang L, Gao W, Sun Y. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer. FEBS Lett 2015; 589(17):2248-56; PMID:26149216; https://doi.org/10.1016/j.febslet.2015.06.037
   PubMed Web of Science ®Google Scholar
• Zhang P, Guo X, Li J, Yu S, Wang L, Jiang G, Yang D, Wei Z, Zhang N, Liu J, et al. Immunoglobulin-like transcript 4 promotes tumor progression and metastasis and up-regulates VEGF-C expression via ERK signaling pathway in non-small cell lung cancer. Oncotarget 2015; 6(15):13550-63; PMID:25948790; https://doi.org/10.18632/oncotarget.3624
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao J, Qiu L, Zhang P, Li J, Yang D, Wei X, Han Y, Nie S, Sun Y. Co-expression of ILT4/HLA-G in human non-small cell lung cancer correlates with poor prognosis and ILT4-HLA-G interaction activates ERK signaling. Tumour Biol 2016; 37(8):11187-98; PMID:26939901; https://doi.org/10.1007/s13277-016-5002-5
   PubMed Web of Science ®Google Scholar
• Morandi F, Rizzo R, Fainardi E, Rouas-Freiss N, Pistoia V. Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases. J Immunol Res 2016; 2016:4326495; PMID:27652273; https://doi.org/10.1155/2016/4326495
   PubMed Web of Science ®Google Scholar
• Hammers H. Immunotherapy in kidney cancer: the past, present, and future. Curr Opin Urol 2016; 26(6):543-7; PMID:27533501; https://doi.org/10.1097/MOU.0000000000000338
   PubMed Web of Science ®Google Scholar
• Escudier B, Kataja V, Group EGW. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2010; 21 Suppl 5:v137-139; PMID:20555064; https://doi.org/10.1093/annonc/mdq206
   PubMed Web of Science ®Google Scholar